Aberdeen Group plc Acquires 6,956 Shares of DaVita Inc. $DVA

Key Points

• Aberdeen Group plc increased its holdings in DaVita Inc. by 16.5%, acquiring an additional 6,956 shares during the second quarter, bringing its total ownership to 49,209 shares valued at approximately $7.01 million.
• DaVita reported earnings of $2.95 per share in its latest quarterly results, beating estimates by $0.25 and achieving a revenue of $3.38 billion, which is a 6.1% increase compared to the same period last year.
• Currently, 90.12% of DaVita's stock is owned by institutional investors, with several hedge funds recently adjusting their positions in the company, indicating significant interest in the firm's future.

Aberdeen Group plc boosted its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 16.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,209 shares of the company's stock after acquiring an additional 6,956 shares during the period. Aberdeen Group plc owned approximately 0.07% of DaVita worth $7,010,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Doma Perpetual Capital Management LLC lifted its holdings in shares of DaVita by 172.3% in the first quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company's stock valued at $44,110,000 after purchasing an additional 182,476 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company's stock valued at $136,240,000 after purchasing an additional 149,858 shares in the last quarter. Nuveen LLC bought a new stake in shares of DaVita in the first quarter valued at about $20,218,000. Rovin Capital UT ADV bought a new stake in shares of DaVita in the first quarter valued at about $18,442,000. Finally, Amundi lifted its holdings in shares of DaVita by 16.0% in the first quarter. Amundi now owns 517,690 shares of the company's stock valued at $79,584,000 after purchasing an additional 71,304 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Trading Down 0.7%

Shares of DVA stock opened at $125.18 on Friday. The stock has a market cap of $8.95 billion, a P/E ratio of 12.31, a price-to-earnings-growth ratio of 0.90 and a beta of 1.13. The stock has a 50 day simple moving average of $132.56 and a 200 day simple moving average of $138.60. DaVita Inc. has a 1 year low of $122.93 and a 1 year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. During the same period in the previous year, the company posted $2.00 earnings per share. The firm's revenue for the quarter was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Insider Activity

In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on DVA shares. Barclays cut their price target on DaVita from $160.00 to $149.00 and set an "equal weight" rating on the stock in a report on Thursday, October 9th. Wall Street Zen downgraded DaVita from a "buy" rating to a "hold" rating in a research report on Saturday, October 11th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of DaVita in a research report on Wednesday, October 8th. Bank of America lowered their target price on DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a research report on Wednesday, September 10th. Finally, Truist Financial set a $140.00 target price on DaVita in a research report on Tuesday. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and an average price target of $153.25.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.